Colorectal Cancer

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Experts on colorectal cancer provide comprehensive insights on the GALAXY study, highlighting key updates that were presented at ASCO GI 2024.

Aparna Parikh, MD, reviews the DYNAMIC trial, which is focused on ctDNA-guided adjuvant therapy in early-stage colorectal cancer.

Stacey Cohen, MD, presents the case of a 39-year-old woman with high-risk stage II colorectal cancer, highlighting how ctDNA helped inform treatment selection.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.

Michael Foote, MD, presents the case of a 50-year-old man with stage III colorectal cancer, highlighting the role of MRD testing in patient monitoring and treatment management.

GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.

The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer.

Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.

A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.

Results from part 3 of the phase 2a CORIST trial found that combining SCO-101 with chemotherapy improved the progression-free survival and clinical benefit rate in patients with metastatic colorectal cancer.

Results from the randomized LASRE trial support the use of laparoscopic-assisted surgery for patients with low rectal cancer.

Liver contrast-enhanced MRI resulted in a change in the local treatment plan for approximately a third of patients with colorectal liver metastases in the CAMINO study.

Adjuvant chemotherapy does not yield an improvement in ctDNA clearance compared with observation among patients with stage II colon cancer in the phase 2/3 COBRA trial.

Disease-free survival benefits with chemotherapy appears to be more prominent in patients with colorectal cancer who are minimal residual disease–positive compared with those minimal residual disease–negative disease.

Neoadjuvant botensilimab plus balstilimab appears to be safe and effective in patients with colorectal cancer regardless of mismatch repair status in the phase 2 NEST-1 trial.

Real-world data suggest a role for noncytotoxic chemotherapy treatments such as EGFR inhibitors beyond the frontline setting for patients with metastatic colorectal cancer.

Results from the phase 3 CheckMate-8HW trial highlight that the safety of frontline nivolumab plus ipilimumab in microsatellite instability–high or mismatch repair deficient is comparable with prior reports.

Real-world data may elucidate the characteristics and factors that influence long-term remission with regorafenib among patients with metastatic colorectal cancer.

Findings from the phase 3 FRESCO-2 trial support fruquintinib’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

The DeFianCe trial is using DKN-01 plus bevacizumab and chemotherapy to determine if a clinical benefit would occur in patients with microsatellite stable colorectal adenocarcinoma.

Data demonstrate efficacy of robotic surgery for colectomies, which is swiftly becoming the 'preferred approach' for surgeons.